Tarek Nafee

572 total citations
32 papers, 340 citations indexed

About

Tarek Nafee is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Surgery. According to data from OpenAlex, Tarek Nafee has authored 32 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cardiology and Cardiovascular Medicine, 16 papers in Internal Medicine and 4 papers in Surgery. Recurrent topics in Tarek Nafee's work include Atrial Fibrillation Management and Outcomes (17 papers), Venous Thromboembolism Diagnosis and Management (16 papers) and Antiplatelet Therapy and Cardiovascular Diseases (10 papers). Tarek Nafee is often cited by papers focused on Atrial Fibrillation Management and Outcomes (17 papers), Venous Thromboembolism Diagnosis and Management (16 papers) and Antiplatelet Therapy and Cardiovascular Diseases (10 papers). Tarek Nafee collaborates with scholars based in United States, United Kingdom and Canada. Tarek Nafee's co-authors include Mathieu Kernéis, Megan K. Yee, C. Michael Gibson, Gerald Chi, Adrian F. Hernandez, Robert A. Harrington, Samuel Z. Goldhaber, Russell D. Hull, Alexander T. Cohen and Serge Korjian and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Tarek Nafee

31 papers receiving 330 citations

Peers

Countries citing papers authored by Tarek Nafee

Since Specialization

Citations

This map shows the geographic impact of Tarek Nafee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tarek Nafee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tarek Nafee more than expected).

Fields of papers citing papers by Tarek Nafee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tarek Nafee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tarek Nafee. The network helps show where Tarek Nafee may publish in the future.

Co-authorship network of co-authors of Tarek Nafee

This figure shows the co-authorship network connecting the top 25 collaborators of Tarek Nafee. A scholar is included among the top collaborators of Tarek Nafee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tarek Nafee. Tarek Nafee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 18034: Intracardiac Bullet: To Fish It Out or Let Love Take the Shot! 2023 ·Circulation ·(unknown), (unknown), Kishore J. Harjai, Hersh S. Maniar, (unknown), Tarek Nafee, (unknown), (unknown), Hanumanth K. Reddy, (unknown)	0
2	Impact of malignancy on In‐hospital mortality, stratified by the cause of admission: An analysis of 67 million patients from the National Inpatient Sample 2021 ·International Journal of Clinical Practice ·Ofer Kobo, Sherry‐Ann Brown, Tarek Nafee, Mohamed O. Mohamed, Kamal Sharma, (unknown), Ariel Roguin, Richard K. Cheng, Mamas A. Mamas	6
3	A virtual-hybrid approach to launching a cardio-oncology clinic during a pandemic 2021 ·Cardio-Oncology ·Sherry‐Ann Brown, Sahishnu Patel, (unknown), (unknown), (unknown), Tarek Nafee, (unknown), (unknown), (unknown), (unknown), (unknown), David Marks, Jorge Saucedo	22
4	Machine learning to predict venous thrombosis in acutely ill medical patients 2020 ·Research and Practice in Thrombosis and Haemostasis ·Tarek Nafee, C. Michael Gibson, (unknown), Megan K. Yee, Mathieu Kernéis, Gerald Chi, (unknown), Adrian F. Hernandez, Russell D. Hull, Ander Cohen, Robert A. Harrington, Samuel Z. Goldhaber	37
5	<p>The AngelMed Guardian® System in the Detection of Coronary Artery Occlusion: Current Perspectives</p> 2020 ·Medical Devices Evidence and Research ·(unknown), (unknown), Gerald Chi, Tarek Nafee, Megan K. Yee, (unknown), Sadaf Sharfaei, (unknown), (unknown), C. Michael Gibson	2
6	Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis 2019 ·Journal of Thrombosis and Thrombolysis ·William J. Gibson, Tarek Nafee, (unknown), Megan K. Yee, Mathieu Kernéis, Magnus Öhman, C. Michael Gibson	39
7	Most Promising Therapies in Interventional Cardiology 2019 ·Current Cardiology Reports ·Mathieu Kernéis, Tarek Nafee, Megan K. Yee, (unknown), (unknown), Michel Zeitouni, (unknown), (unknown), (unknown), Iqra Qamar, (unknown), Arzu Kalaycı, (unknown), C. Michael Gibson	8
8	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy 2018 ·The American Journal of Medicine ·Gerald Chi, C. Michael Gibson, Adrian F. Hernandez, Russell D. Hull, (unknown), Ahmed Younes, (unknown), (unknown), Amandeep Singh, Farima Kahe, Arzu Kalaycı, Tarek Nafee, Mathieu Kernéis, (unknown), Alexander T. Cohen, Robert A. Harrington, Samuel Z. Goldhaber	39
9	Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 2018 ·Progress in Cardiovascular Diseases ·Mathieu Kernéis, (unknown), Tarek Nafee, Yazan Daaboul, (unknown), (unknown), (unknown), (unknown), (unknown), Ahmed Younes, C. Michael Gibson	3
10	D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy) 2018 ·The American Journal of Cardiology ·(unknown), Mathieu Kernéis, Tarek Nafee, Megan K. Yee, Gerald Chi, Alexei N. Plotnikov, Eugene Braunwald, C. Michael Gibson	26
11	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention 2018 ·JACC: Cardiovascular Interventions ·Mathieu Kernéis, C. Michael Gibson, Gerald Chi, Roxana Mehran, (unknown), (unknown), (unknown), (unknown), Christoph Bode, Jonathan L. Halperin, Tarek Nafee, Eric D. Peterson, Freek W.A. Verheugt, Peter Wildgoose, Martin van Eickels, Gregory Y.H. Lip, Keith A.A. Fox, Marc Cohen	20
12	P251Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial 2018 ·European Heart Journal ·Arzu Kalaycı, C. Michael Gibson, Gerald Chi, Megan K. Yee, Serge Korjian, (unknown), Tarek Nafee, (unknown), (unknown), Russell D. Hull, Adrian F. Hernandez, Alexander T. Cohen, Robert A. Harrington, Samuel Z. Goldhaber, (unknown)	1
13	Abstract 20393: Full-Dose Betrixaban Reduces Venous Thromboembolism-Related Mortality: An APEX Trial Substudy 2017 ·Circulation ·C. Michael Gibson, Tarek Nafee, Samuel Z. Goldhaber, Adrian F. Hernandez, Russell D. Hull, Alex Gold, Serge Korjian, Yazan Daaboul, Alexander T Cohen, Robert A. Harrington, Gerald Chi	2
14	Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors 2017 ·Expert Review of Cardiovascular Therapy ·Tarek Nafee, Aysha Aslam, Gerald Chi, (unknown), (unknown), Aravind Reddy Kuchkuntla, (unknown), (unknown), Yazan Daaboul, Serge Korjian, Anthony E. Gallo, C. Michael Gibson	7
15	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial 2017 ·Journal of Thrombosis and Thrombolysis ·Megan K. Yee, Tarek Nafee, Yazan Daaboul, Serge Korjian, (unknown), Mathieu Kernéis, (unknown), Samuel Z. Goldhaber, Adrian F. Hernandez, Russell D. Hull, Alexander T. Cohen, Robert A. Harrington, C. Michael Gibson	10
16	Abstract 20322: Extended-Duration Betrixaban Reduces the Risk of Venous Thromboembolism-Related Rehospitalization Among Acutely Ill Hospitalized Medical Patients: An APEX Trial Substudy 2017 ·Circulation ·Gerald Chi, Tarek Nafee, Samuel Z. Goldhaber, Adrian F. Hernandez, Russell D. Hull, Alex Gold, Serge Korjian, Yazan Daaboul, Alexander T Cohen, Robert A. Harrington, C. Michael Gibson	1
17	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients 2017 ·American Heart Journal ·C. Michael Gibson, Tarek Nafee, Megan K. Yee, Gerald Chi, Serge Korjian, Yazan Daaboul, (unknown), Mathieu Kernéis, Samuel Z. Goldhaber, Russel Hull, Adrian F. Hernandez, Alexander T. Cohen, Robert A. Harrington	16
18	ASSERT trial – How to assess the safety and efficacy of a high frequency rTMS in postpartum depression ? A multicenter, double blinded, randomized, placebo-controlled clinical trial 2017 ·Contemporary Clinical Trials Communications ·(unknown), (unknown), Tarek Nafee, (unknown), Mahmoud Mohamed, (unknown), Ana Ganho-Ávila, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Karen J. Campoverde Reyes, (unknown), Hiroki Nishiwaki, (unknown)	6
19	Effects of noninvasive brain stimulation in cerebral stroke related vision loss 2015 ·(unknown), (unknown), Tarek Nafee	2
20	Effects of transcranial direct current stimulation on working memory in healthy older adults: a systematic review 2015 ·(unknown), Tarek Nafee, Adriana Sampaio, Jorge Leite, Sandra Carvalho	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact